People · Operator
Named in public records as an officer, director or promoter · active 2018–2022 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Xenter, Inc. | — | Biotechnology | Series B | $23.5M | $15.5M | 2021 |
| PanTher Therapeutics, Inc. | — | Pharma | Series A | $15.8M | $11.4M | 2018 |
Elazer Edelman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Elazer Edelman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| John Edwards | 1 | 8 |
| ROBERT BAXTER | 1 | 7 |
| Darshana Zaveri | 1 | 5 |
| David Bearss | 1 | 5 |
| Richard Linder | 1 | 3 |
| MARK STAUTBERG | 1 | 3 |
| Maria Palasis | 1 | 2 |
| David Ting | 1 | 2 |
| Manish Bhandari | 1 | 2 |
| David Sampson | 1 | 1 |
| Laura Indolfi | 1 | 1 |
| D Mackey | 1 | 1 |
| Daniel Wildman | 1 | 1 |
| James Tobin | 1 | 1 |
| Eric Pearson | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.